Home    Back

Nerve growth factor    (DrugBank: Nerve Growth Factor)

2 diseases
IDDisease name (Link within this page)Number of trials
3Spinal muscular atrophy1
90Retinitis pigmentosa2

3. Spinal muscular atrophy    [ 179 clinical trials,   102 drugs,   (DrugBank: 26 drugs),   52 drug target genes,   78 drug target pathways]
Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 179 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR-TRC-10001093
2010-10-012010-11-02Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trialRat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial children with spinal muscular atrophyA:Rat nerve growth factor injection for six monthes,;B:Rat nerve growth factor injection for six monthes,;PLA General HospitalNULLCompleted38BothA:20;B:20;China

90. Retinitis pigmentosa    [ 103 clinical trials,   158 drugs,   (DrugBank: 42 drugs),   52 drug target genes,   107 drug target pathways]
Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 103 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02609165
(ClinicalTrials.gov)		May 201512/10/2015Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaNerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II TrialRetinitis Pigmentosa;Cystoid Macular EdemaDrug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye dropsOspedale San RaffaeleDompé Farmaceutici S.p.ACompleted18 YearsN/AAll45Phase 2Italy
2EUCTR2014-000385-22-IT
(EUCTR)		07/10/201412/05/2014Nerve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa.Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical toclinical Phase II trial. - NEMO Retinitis pigmentosa with cystoid macular edema
MedDRA version: 17.0;Level: LLT;Classification code 10054467;Term: Macular edema;System Organ Class: 100000004853
MedDRA version: 17.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]		Product Name: recombinant human Nerve Growth Factor (rhNGF)
INN or Proposed INN: not yet assigned
Other descriptive name: RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF)		Ospedale San Raffaele di MilanoNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Phase 2Italy